Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

RecruitingLast updated: 7 August 2026

STELLAR-311: Comparing two targeted therapies for people with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumours.A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

Trial purpose

Medical clipboardCancer treatment

Tumor type

Neuroendocrine tumours Neuroendocrine tumours

Age

People18+

Trial acronym

STELLAR-311

Clinical summary

Summary

This clinical trial is testing whether a targeted cancer treatment called zanzalintinib works better than everolimus, an approved treatment for some neuroendocrine tumours (NETs), in people whose cancer has grown, spread, or cannot be removed with surgery.

Neuroendocrine tumours are a type of cancer that can develop in the pancreas or other parts of the body, such as the digestive system or lungs.

Who may be able to join?
You may be eligible if:

  • you are aged 18 years or older
  • you have a well-differentiated neuroendocrine tumour that started in the pancreas or another organ
  • your cancer is locally advanced, unresectable or metastatic
  • you have received previous treatment for your NET
  • your cancer has shown signs of worsening or growing within the last 12 months

Some people will not be eligible, including those who have previously received certain targeted treatments, such as VEGFR-targeting drugs or mTOR inhibitors, or who have received some recent cancer treatments.

What treatment will participants receive?
Participants are randomly assigned (by chance) to receive either:

  • Zanzalintinib (the investigational treatment), or
  • Everolimus (an approved treatment for some neuroendocrine tumours).

Researchers want to determine whether zanzalintinib can control neuroendocrine tumours for longer or more effectively than everolimus, while also evaluating safety and side effects. 

Conditions

This trial is treating people with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors of pancreatic origin or extra-pancreatic origin.

Eligibility

Inclusion

  • Histologically confirmed, locally advanced/unresectable or metastatic, well-differentiated Grade 1, 2, or 3 NETs of pancreatic origin or extra-pancreatic origin.
  • Allowed prior lines of therapy, based on the site of NET and functional status.
  • Documented radiographic disease progression per RECIST 1.1, as assessed by the Investigator based on imaging assessments (computed tomography [CT] or magnetic resonance imaging [MRI]) within 12 months before randomization.
  • Measurable disease according to RECIST 1.1 as determined by the Investigator.
  • Archival tumor tissue is required, if available. If archival tumor tissue is not available, a fresh biopsy may be submitted if it can be safely and feasibly obtained. Every attempt should be made to provide tumor tissue.

Exclusion

  • Histologically confirmed neuroendocrine carcinomas (including small cell lung cancer), medullary thyroid cancer, pheochromocytoma, paraganglioma, Merkel cell carcinoma, and mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN).
  • Prior treatment with a vascular endothelial growth factor receptor (VEGFR) -targeting tyrosine kinase inhibitor or a mammalian target of rapamycin (mTOR) inhibitor.
  • Systemic chemotherapy and any liver-directed or other ablative therapy within 4 weeks before randomization.
  • Systemic radionuclide therapy within 6 weeks before randomization.
  • Radiation therapy for bone metastases within 2 weeks, any other radiation therapy, except as indicated above, within 4 weeks before randomization.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Inclusion

  • Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
  • Your cancer has not spread to other parts of the body, but it is not possible to perform surgery to remove it (unresectable).
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

Exclusion

  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ClinicalTrials.gov, EU Clinical Trials Register *. View further details about this trial on the registry via the links below:

Trial sponsor

Exelixis

Scientific Title

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

Trial added to VCTL (data sourced from registry): March 2026
Trial information last reviewed by VCTL: August 2026

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information